We are a team of seasoned entrepreneurs taking on one of the largest industries in the world - financial services and insurance. But we can’t do it alone and are looking for exceptional people to join us. We are the fastest-growing AI company specializing in all things outdoor adventure compliance. Our software suite provides small business owners with the products and services required to be compliant with their local rules and regulations. We are starting with boats, which makes us the first AI-driven boating company in the world. With significant backing from top investors and experienced operators, we are committed to leveraging state-of-the-art technology to create a world where everyone can safely access adventure forever.

Arctic Outdoor is a new danish outdoor brand focusing on creating outdoor products and equipment, built to last and apply all technical features to ensure you are well prepared for your next adventure. We have a vision that we want to create an outdoor community with a solid engagement with our community members and product owners. We have connected each of our products to a coordinate around the world to try and inspire people to get outdoors and experience new things and move boundaries.

Vocaire is a startup that focuses on empowering physical therapists with AI technologies. The problem we are solving is that PTs cannot be 100% present during their consultation since they have to focus on administrative work and other tasks. The founders of our startup are previous elite sportsmen who experienced firsthand the inefficiencies of the current system. Physical therapy is a crucial part of the recovery process for many individuals who have experienced injuries or other physical limitations. However, the current system is highly inefficient and often requires PTs to spend a significant amount of time on administrative tasks. For example, PTs may have to spend time scheduling appointments, documenting patient progress, and communicating with other healthcare providers. This leaves less time for PTs to focus on their patients and provide the best possible care. At Vocaire, we believe that technology can help alleviate this problem. By leveraging AI and other advanced technologies, we aim to streamline administrative tasks and give PTs more time to focus on their patients. Overall, we believe that Vocaire has the potential to significantly improve the efficiency and effectiveness of physical therapy. By leveraging AI and other advanced technologies, we aim to empower PTs to provide the best possible care to their patients. We are excited about the potential of our platform and look forward to continuing to innovate in this space.

Med-Storm's Skin Conductance Algesimeter (SCA) uses the principle of skin conductance to measure pain, allowing us to titrate the right amount of pain medication for each, individual patient. This award-winning technology is not affected by changes in blood circulation, heart rate, hypotensia, environmental temperatures, and hypoxia, and shows low variation between individuals at the same level of pain. The pain monitor can be used on patients as young as 23 weeks of gestational age, as well as geriatric patients. MS is currently working on a miniaturized and wireless version of the SCA.

Bookify is a nationwide search portal targeted to anyone planning meetings, events, conferences, kick-offs, and much more. With different search criteria and filters, you`ll have simple access to meetings and conference venues adapted to your standards. Quick and Easy. Bookify makes it easy to find meeting rooms, function rooms and conference rooms. We also simplify the process for people who have a suitable premise they want to rent out but do not know how to proceed. In the app you can quickly find premises near you, it is easy to find the premises that have the facilities you are looking for and payment is done seamlessly right in the app! The app uses geolocation so that you can quickly book the premises you are looking for. At the same time, you can also do more advanced searches to book ahead of time. You have a full overview of upcoming meeting rooms, payment history and receipt archives. In addition, you can add premises you use often as favorites to make the booking process even easier and faster!

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

A bio-and medtech Company developing and selling proprietary solutions for using oxygen in various applications. Currently focussing on beverages (water, sports- and isotonic drinks), wound healing, cosmetics and fish farming. Licensing platform technology for applying oxygent to other products. Oxy Solutions is a privately held Norwegian based biotech company that has developed and patented an innovative technology for highly oxygenating liquid. Oxy Solutions'​ core business and strategy is to develop, document, IP protect, and commercialize the technology primarily within wound healing. The company has an in-house R&D facility in Norway. The company has funding from the Norwegian Research Council. Oxy Solutions is in possession of patented technology that makes it possible to greatly increase the dissolved level of oxygen in water. Tests have indicated stable levels in excess of 70 mg/l, or approximately 10 times higher than previously thought possible.

Bytt.no er Norges største sammenligningstjeneste for tjenester og produkter innen personlig økonomi. Hver dag bruker tusenvis av nordmenn Bytt.no for å lese verifiserte brukeromtaler om selskaper og sammenligne priser på tusenvis av tjenester og produkter. Vi er en rendyrket IT-bedrift innen fintech og insurtech som digger å løse problemer ved hjelp av ny teknologi. Vårt primære mål er å koble nye kunder med gode bedrifter. Vi jobber med å forenkle, tilgjengeliggjøre og sammenligne tradisjonelt gammeldagse og lite transparente bransjer ved hjelp av teknologi og smarte løsninger. Lyst til å jobbe med oss? Vi har ledige stillinger, sjekk: www.bytt.no/jobb

The Norwegian fashion brand BRGN was founded in 2015 by Ros-Mari Tobiassen Gaundal and Karine Trellevik Lunde. Their mission is to offer great alternatives to the traditional all-weather jacket, through high-quality garments and shoes that can be worn on any occasion and in any kind of weather. Their technical and waterproof products, designed for a functional and urban lifestyle, are now sold by over a hundred retailers in Norway, Germany, France, and the UK in addition to their two concept stores in Oslo and Bergen. BRGN set a new turnover record in 2021, at 25.8 MNOK. Up from 16. MNOK in 2020.

We’re an independent game studio based in Oslo, Norway, which was founded in February 2013 by a group of students at the Norwegian School of Information Technology (NITH). In January 2014 we consisted of 7 members of the team who all have different experiences in their own fields of expertise. Our common goal is that we want to contribute to the indie scene with story-driven games, without compromising the gameplay. Starting up a new company (let alone within gaming) is no joke, and we hope to make it easier for future companies to make games. It’s a small pond, and as soon as we announce our projects, our vision is to have an exposed development during production. So keep an eye on our development blog on our page, or contact us if you want to know anything! We are currently working on a third-person horror game, set in a forest inspired by Norwegian nature.

Eat Grim is on a mission to fix our broken food system by fundamentally changing the way people eat. Eat Grim is a platform for ugly and surplus fruits and vegetables. We source the produce directly from farms and bring it back into the food system through a food box subscription that we sell to private consumers, making it easy to eat more sustainably - with exciting business expansion in the pipeline. Every kilo of food sold through Eat Grim is a kilo of food saved from going to waste, which also means savings in water, CO2 and land use along the value chain.

We have decided to radically change the way insurances are sold today. Instead of asking what the customer wants, we tell him what he needs. This we do by extracting intelligent insights from public available data and combing this with machine learning models trained on an insurance company’s existing portfolio.

We're the Danish sperm bank with higher standards, but we're so much more. With a team of visionaries and builders, we're on the road to rethinking the entire structure of the fertility industry. Better connected, smoother processes. Higher standards. Nordic sperm bank with IQ screening, criminal background checks and fertility staff approvals. Software-as-a-service and process-as-a-service provider for fertility clinics and producing sperm banks. Support team providing personalized and comprehensive guidance to match individual family needs.

BetterLabs revolutioner adgangen til sundhedsdata for private ved at give adgang til blodprøver der tidligere var forbeholdt praktiserende læger og hospitaler. Vi samarbejder med næsten 70 prøvesteder, og dækker dermed hele Danmark. De mest solgte prøver er stofskifte test, testosteron test og dybdegående sundhedstjek. Vi skabte BetterLabs da vi selv manglede bedre adgang til blodprøver til brug for sundhedsoptimering og fysisk performance.